PMID- 34938661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular 
      Melanoma: A Systematic Review and Meta-Analysis.
PG  - 781162
LID - 10.3389/fonc.2021.781162 [doi]
LID - 781162
AB  - AIM: This meta-analysis aimed to compare the efficacy and safety of immune 
      checkpoint blockade for the treatment of ocular melanoma. METHODS: We searched 
      the PubMed, EMBASE, and Cochrane Library databases up to July 2021. Effect sizes 
      (ESs) and corresponding 95% confidence intervals (CIs) were used to compare the 
      outcomes. Efficacy outcomes included complete response (CR), partial response 
      (PR), stable disease (SD), progressive disease (PD), objective response rate 
      (ORR), overall survival (OS), progression free survival (PFS). Safety outcomes 
      included adverse events (AEs) and serious adverse event (SAEs). RESULTS: A total 
      of 16 eligible articles with 848 ocular melanoma patients were included. ICB 
      treatment significantly improved CR (ES=0.02, 95%CI: 0.00-0.03, P=0.023), PR 
      (ES=0.07, 95%CI: 0.05-0.09, P=0.000), SD (ES=0.31, 95%CI: 0.17-0.46, P=0.000), PD 
      (ES=0.69, 95%CI: 0.61-0.77, P=0.000), ORR (ES=0.10, 95%CI: 0.04-0.15, P=0.000), 
      OS (ES=9.68, 95%CI: 7.28-12.07, P=0.000) and PFS (ES=2.88, 95%CI: 2.69-3.07, 
      P=0.000) in patients with ocular melanoma. Moreover, ICB therapies were 
      associated with reduced AEs (ES=0.48, 95%CI: 0.30-0.67, P=0.000) and SAEs 
      (ES=0.31, 95%CI: 0.18-0.45, P=0.000). CONCLUSIONS: ICB therapy showed good 
      efficacy and safety in treating patients with ocular melanoma.
CI  - Copyright (c) 2021 Zhao, Xia, Zhang, Zou, Zhu and Zhang.
FAU - Zhao, Lu
AU  - Zhao L
AD  - Department of Biopharmaceutics, School of Life Science and Bio-Pharmaceutics, 
      Shenyang Pharmaceutical University, Shenyang, China.
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Shenyang Medical College, Shenyang, China.
FAU - Xia, Wenwen
AU  - Xia W
AD  - Department of Biopharmaceutics, School of Life Science and Bio-Pharmaceutics, 
      Shenyang Pharmaceutical University, Shenyang, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - School of Traditional Chinese Medical, Shenyang Medical College, Shenyang, China.
FAU - Zou, Peng
AU  - Zou P
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Shenyang Medical College, Shenyang, China.
FAU - Zhu, Qiwen
AU  - Zhu Q
AD  - Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province, 
      Shenyang Medical College, Shenyang, China.
FAU - Zhang, Rong
AU  - Zhang R
AD  - Department of Biopharmaceutics, School of Life Science and Bio-Pharmaceutics, 
      Shenyang Pharmaceutical University, Shenyang, China.
LA  - eng
PT  - Systematic Review
DEP - 20211206
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8685375
OTO - NOTNLM
OT  - CTLA-4
OT  - PD-1
OT  - PD-L1
OT  - immune checkpoint blockade
OT  - meta-analysis
OT  - ocular melanoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/24 06:01
PMCR- 2021/01/01
CRDT- 2021/12/23 05:52
PHST- 2021/09/22 00:00 [received]
PHST- 2021/11/10 00:00 [accepted]
PHST- 2021/12/23 05:52 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.781162 [doi]
PST - epublish
SO  - Front Oncol. 2021 Dec 6;11:781162. doi: 10.3389/fonc.2021.781162. eCollection 
      2021.